HepaTx, a preclinical-stage biotechnology company developing cell therapies for liver disease, is proud to announce the addition of Dr. Avnesh Thakor
Palo Alto, 9/12/2023 – HepaTx, a preclinical-stage biotechnology company developing cell therapies for liver disease, is proud to announce the addition of Dr. Avnesh Thakor to its esteemed Scientific Advisory Board. Dr. Thakor’s remarkable career and groundbreaking research in interventional radiology and mesenchymal stem cell biology make him a valuable asset to Hepatx’s cell therapy programs.
Dr. Thakor is an adult and pediatric-certified Interventional Radiologist whose vision and research are focused on developing the area of “Precision Delivery” in which targeted delivery approaches are used to locally deliver drug, gene, cell, and cell-free therapies directly to organs using image-guided approaches. As a physician-scientist, Dr. Thakor also makes sure that these innovations (i.e. technologies, therapies, and devices) are effectively translated from the benchtop to the beside; to that effect, he is a PI and Co-I on several clinical trials, a successful entrepreneur who has helped found companies, and also serves as an advisor for start-ups as well as established larger biotechnology companies.
“We are thrilled to welcome Dr. Thakor to our Scientific Advisory Board,” said Eric Schuur, CEO of HepaTx. “His expertise in interventional radiology and his visionary approach to Precision Delivery align perfectly with our mission to transform liver disease treatments. Dr. Thakor’s insights will be instrumental in shaping our clinical trial strategies and accelerating the development of innovative therapies.”
“I am excited to join HepaTx’s Clinical Advisory Board and contribute to the development of groundbreaking therapies for liver diseases,” said Dr. Thakor. “HepaTx’s dedication to advancing patient care aligns perfectly with my own vision. I look forward to collaborating with the exceptional team at HepaTx and contributing to the success of their cell therapy initiatives.”
Dr. Thakor’s inclusion in the Scientific Advisory Board reaffirms HepaTx’s commitment to assembling a world-class team of experts to guide its clinical efforts. With Dr. Thakor’s insights, HepaTx is ready to achieve new heights in innovation and patient-centered liver disease treatments.
About HepaTx
HepaTx is a cell therapy and regenerative medicine company developing cell-based treatments for late-stage liver disease, a highly underserved and cost-intensive market. To learn more, visit our website, Hepatx.com, and follow us on Twitter, @hepatx, and LinkedIn.
Contact:
HepaTx
Claudia Preziosi
cpreziosi@hepatx.com